Trademark Attorney / Law Firm

Brenda Glaser Abrams, Esquire – Trademark Portfolio

Brenda Glaser Abrams, Esquire has filed 4 trademarks with the United States Patent and Trademark Office (USPTO). Filing records are from 2013. The portfolio covers 4 Nice Classification classes, with the highest concentration in Class 42 (Computer & Scientific, 1 filings) and Class 36 (Insurance & Financial, 1 filings).

4 Total Trademarks
Loading...
By Date
By Name
Filter by Class:

Practice Areas by Trademark Class

Brenda Glaser Abrams, Esquire's trademark practice covers 4 Nice Classification classes, representing the range of industries and goods/services handled in their USPTO filings.

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

36
Insurance & Financial (1 filing)

Insurance; financial affairs; monetary affairs; real estate affairs

44
Medical Services (1 filing)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademark applications has Brenda Glaser Abrams, Esquire filed?

Brenda Glaser Abrams, Esquire has filed 4 trademark applications with the United States Patent and Trademark Office (USPTO).

What trademark classes does Brenda Glaser Abrams, Esquire specialize in?

Brenda Glaser Abrams, Esquire has filed trademarks across 4 Nice Classification classes. The most common practice areas include Class 42 (Computer & Scientific), Class 36 (Insurance & Financial), Class 44 (Medical Services), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.

What is Brenda Glaser Abrams, Esquire's trademark registration success rate?

Brenda Glaser Abrams, Esquire has a 0% trademark registration rate, with 0 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.